ECSP20058183A - Inhibidores de arginasa y sus métodos de uso - Google Patents
Inhibidores de arginasa y sus métodos de usoInfo
- Publication number
- ECSP20058183A ECSP20058183A ECSENADI202058183A ECDI202058183A ECSP20058183A EC SP20058183 A ECSP20058183 A EC SP20058183A EC SENADI202058183 A ECSENADI202058183 A EC SENADI202058183A EC DI202058183 A ECDI202058183 A EC DI202058183A EC SP20058183 A ECSP20058183 A EC SP20058183A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- compounds
- formula
- arginase inhibitors
- arginase
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title abstract 2
- 108700024123 Arginases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se divulgan compuestos de fórmula (Ia) o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden compuestos de fórmula (Ia) y métodos para utilizarlas en el tratamiento del cáncer o una enfermedad respiratoria inflamatoria y la inhibición de la arginasa: donde R1 es -NHR1a; R1a es -H o -C(O)CH(R1b)NHR1c; y R1b se selecciona entre -H, -alquilo (C1-C4) y CH2OR1d y R1c es -H; o R1b y R1c, junto con el átomo al que están unidos, forman un anillo heterocíclico de 5 miembros; y R1d es H o CH3;
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862631659P | 2018-02-17 | 2018-02-17 | |
US201862671576P | 2018-05-15 | 2018-05-15 | |
US201862721113P | 2018-08-22 | 2018-08-22 | |
US201862778002P | 2018-12-11 | 2018-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP20058183A true ECSP20058183A (es) | 2020-10-30 |
Family
ID=65763693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202058183A ECSP20058183A (es) | 2018-02-17 | 2020-09-16 | Inhibidores de arginasa y sus métodos de uso |
Country Status (22)
Country | Link |
---|---|
US (3) | US11420984B2 (es) |
EP (1) | EP3752251A1 (es) |
JP (2) | JP7317841B2 (es) |
KR (1) | KR102657919B1 (es) |
CN (3) | CN117180290A (es) |
AU (2) | AU2019221896B2 (es) |
BR (1) | BR112020015973A2 (es) |
CA (1) | CA3091365A1 (es) |
CL (1) | CL2020002096A1 (es) |
CR (1) | CR20200418A (es) |
DO (1) | DOP2020000145A (es) |
EC (1) | ECSP20058183A (es) |
IL (1) | IL276711B2 (es) |
JO (1) | JOP20200197A1 (es) |
MA (1) | MA51837A (es) |
MX (1) | MX2020008570A (es) |
NI (1) | NI202000055A (es) |
PE (1) | PE20210176A1 (es) |
SG (1) | SG11202007739XA (es) |
TW (1) | TWI803574B (es) |
UY (1) | UY38096A (es) |
WO (1) | WO2019159120A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019159120A1 (en) * | 2018-02-17 | 2019-08-22 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
CA3094939A1 (en) | 2018-03-29 | 2019-10-03 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | A2a/a2b阻害剤としての縮合ピリミジン誘導体 |
EP3818063A1 (en) | 2018-07-05 | 2021-05-12 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
PT3840837T (pt) * | 2018-08-22 | 2024-06-14 | Astrazeneca Ab | Inibidores de arginase e métodos de uso dos mesmos |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
MA56324B1 (fr) * | 2019-02-08 | 2023-10-31 | Astrazeneca Ab 151 85 Soedertaelje | Inhibiteurs de l'arginase et leurs procédés d'utilisation |
EP4054591A1 (en) * | 2019-11-04 | 2022-09-14 | Astrazeneca AB | Combination therapy for treating cancer |
TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103068830B (zh) * | 2010-04-22 | 2016-06-29 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
PL2632927T3 (pl) | 2010-10-26 | 2016-09-30 | Boroniany jako inhibitory arginazy | |
RU2019121905A (ru) | 2010-12-31 | 2019-09-03 | Астразенека Юкей Лимитед | Ингибиторы аргиназы и способы их применения |
CN104540836B (zh) | 2012-04-18 | 2016-11-09 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
WO2016210106A1 (en) * | 2015-06-23 | 2016-12-29 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
SI3368541T1 (sl) | 2015-10-30 | 2020-10-30 | Calithera Biosciences, Inc. | Sestavki in postopki za zaviranje arginazne dejavnosti |
PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
WO2018089490A1 (en) * | 2016-11-08 | 2018-05-17 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
PT3559009T (pt) | 2016-12-22 | 2021-05-04 | Calithera Biosciences Inc | Composições e métodos para inibir a atividade da arginase |
CN111491937A (zh) | 2017-12-22 | 2020-08-04 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的杂环化合物 |
WO2019159120A1 (en) * | 2018-02-17 | 2019-08-22 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
EP3765006A4 (en) | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
CN111770756B (zh) | 2018-04-27 | 2023-03-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
WO2019218904A1 (zh) | 2018-05-18 | 2019-11-21 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、其制备方法及用途 |
EP3810615A4 (en) | 2018-06-20 | 2022-03-30 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
-
2019
- 2019-02-15 WO PCT/IB2019/051236 patent/WO2019159120A1/en active Application Filing
- 2019-02-15 JP JP2020543307A patent/JP7317841B2/ja active Active
- 2019-02-15 BR BR112020015973-5A patent/BR112020015973A2/pt unknown
- 2019-02-15 PE PE2020001241A patent/PE20210176A1/es unknown
- 2019-02-15 UY UY0001038096A patent/UY38096A/es unknown
- 2019-02-15 US US16/969,739 patent/US11420984B2/en active Active
- 2019-02-15 JO JOP/2020/0197A patent/JOP20200197A1/ar unknown
- 2019-02-15 TW TW108105043A patent/TWI803574B/zh active
- 2019-02-15 SG SG11202007739XA patent/SG11202007739XA/en unknown
- 2019-02-15 CN CN202311157009.9A patent/CN117180290A/zh active Pending
- 2019-02-15 CR CR20200418A patent/CR20200418A/es unknown
- 2019-02-15 CN CN201980013045.3A patent/CN111712302B/zh active Active
- 2019-02-15 AU AU2019221896A patent/AU2019221896B2/en active Active
- 2019-02-15 EP EP19710796.4A patent/EP3752251A1/en active Pending
- 2019-02-15 MA MA051837A patent/MA51837A/fr unknown
- 2019-02-15 KR KR1020207026580A patent/KR102657919B1/ko active IP Right Grant
- 2019-02-15 IL IL276711A patent/IL276711B2/en unknown
- 2019-02-15 CA CA3091365A patent/CA3091365A1/en active Pending
- 2019-02-15 MX MX2020008570A patent/MX2020008570A/es unknown
- 2019-02-15 CN CN202311155200.XA patent/CN117186134A/zh active Pending
-
2020
- 2020-07-22 DO DO2020000145A patent/DOP2020000145A/es unknown
- 2020-08-13 CL CL2020002096A patent/CL2020002096A1/es unknown
- 2020-08-14 NI NI202000055A patent/NI202000055A/es unknown
- 2020-09-16 EC ECSENADI202058183A patent/ECSP20058183A/es unknown
-
2022
- 2022-06-07 AU AU2022203938A patent/AU2022203938B2/en active Active
- 2022-07-15 US US17/812,736 patent/US20230122859A1/en active Pending
-
2023
- 2023-07-10 US US18/349,336 patent/US11912727B2/en active Active
- 2023-07-19 JP JP2023117406A patent/JP2023145557A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20058183A (es) | Inhibidores de arginasa y sus métodos de uso | |
CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
PE20230238A1 (es) | Inhibidores de kras g12c | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR111820A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue | |
AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CO6251294A2 (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer | |
CL2021002165A1 (es) | Nuevos derivados de compuestos heterociclicos y uso de los mismos | |
PE20190106A1 (es) | Inhibidores del potenciador del homologo zeste 2 | |
AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
PE20212070A1 (es) | Moduladores de trex1 | |
AR114420A1 (es) | Derivados de 2,4-diaminoquinazolina y usos médicos de los mismos | |
PE20161369A1 (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
CY1123864T1 (el) | Νεα παραγωγα αμινο-ιμιδαζοπυριδινης σαν αναστολεις κινασης janus και φαρμακευτικες χρησεις | |
DOP2021000166A (es) | Inhibidores de arginasa y métodos de uso de estos | |
CO6180505A2 (es) | Metodos para el tratamiento de transtornos cocleares y vestibulares | |
AR088775A1 (es) | Derivados heterociclicos diazeniodiolato de amina primaria | |
EA202091886A1 (ru) | Ингибиторы аргиназы и способы их применения | |
AR101413A1 (es) | Inhibidores de la tirosina cinasa de bruton | |
AR114394A1 (es) | Inhibidores de arginasa y sus métodos de uso | |
AR114666A1 (es) | Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer |